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To the Editor: 
 
We read with great interest the recent study published by Kuper et al. 1, where the authors 
randomized pregnant smokers and non-smokers women to receive intramuscularly either 17 alpha-
hydroxyprogesterone caproate, an omega-3 fatty acid, or placebo from the 16-20th week of 
gestation till the delivery, evaluating its effect on the preterm delivery rate and both maternal and 
neonatal complications.  
The authors should be congratulated for the randomized study design and the presence of ethnic 
variability in the examined population, and, nonetheless, to have found a significant reduction of the 
spontaneous preterm delivery rate and low birth weight thanks to the anti-oxidative agent 
supplementation in smoker mothers in comparison to non-smokers 1. 
However, we would like to point out some methodological concerns on the prevention of the 
secondary outcomes examined in the study, in particular dealing with neonatal complications. The 
authors did not report a significant treatment effect in reducing neonatal complications both in the 
groups of smokers and not smokers 1. Concerning this finding, we believe that the smokers 
population receiving antioxidant supplementation is relatively small (64/851) and, therefore, the 
statistical power of the study could have been limited by the small sample size. In contrast with the 
findings in this study, in the literature it is well known the positive association between the 
oxidative damage due to maternal smoke and the increased incidence of neonatal complications 
such as bronchopulmonary dysplasia (BPD), intraventricular hemorrhage, and retinopathy of 
prematurity 2. On this regard, several clinical studies showed that the maternal supplementation of 
vitamin A, which exerts antioxidant activity, during the late phase of pregnancy, is effective in 
decreasing BPD incidence in newborns 3. Moreover, in line with this findings, Sharma et al. found 
in the rat model that the maternal supplementation with polyunsaturated fatty acids ω-3 (PUFA ω-3) 
decreases significantly the neonatal onset of BPD, especially protecting the reduction of 
alveolarization caused by the hyperoxia-induced oxidative damage 4. 
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Given these assumptions, we deem that omega-3 fatty acid supplementation should be more 
thoroughly investigated for preventing the onset of neonatal complications for at least two reasons: 
firstly, their efficacy in reducing significantly the preterm delivery rate in smoker mothers and 
secondly through the already proven protective effect during pregnancy. Thus, further larger scale 
studies should be performed in order to better understand the potential effect of antioxidant agents 
administration in pregnancy of smoker women.  
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